咪喹莫特治疗弥漫性结膜原位黑色素瘤或眼表鳞状上皮肿瘤
本干预性病例系列研究纳入5例组织学诊断为结膜上皮内瘤变、结膜鳞状细胞癌、结膜原位黑色素瘤或结膜黑色素瘤伴邻近原发性获得性黑变病的患者,接受复合咪喹莫特5%眼膏每周5天、至少12周(范围12-15周)治疗并联合局部抗生素。结果显示部分患者达到完全或部分临床及组织学缓解,所有患者仅出现眼表及眼睑不良事件并在停药或完成治疗后1至2周内消退;作者认为复合咪喹莫特5%眼膏可能是管理弥漫性结膜原位黑色素瘤或眼表鳞状上皮肿瘤的安全有效方法,但仅5例无法确定确切安全性和疗效,需更长期随访和更大样本。
要点
- 5例患者接受复合咪喹莫特5%眼膏每周5天、至少12周(范围12-15周)联合局部抗生素治疗。
- 12周时结膜上皮内瘤变伴中度异型增生达完全临床和组织学缓解,鳞状细胞癌部分组织学缓解,原位黑色素瘤部分临床缓解但初始活检区域完全组织学缓解。
- 所有患者仅出现眼表和眼睑不良事件,均在停药或完成治疗后1至2周内消退。
核心结论
- 研究结果提示,尽管仅5例无法确定确切安全性和疗效,复合咪喹莫特5%眼膏可能是管理弥漫性结膜原位黑色素瘤或眼表鳞状上皮肿瘤的安全有效方法。
- 需要更长期随访和更大样本量。
研究设计与样本
- 干预性病例系列研究,于2024年6月至2025年3月在一家三级转诊中心开展。
- 纳入5例组织学诊断为结膜上皮内瘤变、结膜鳞状细胞癌、结膜原位黑色素瘤或结膜黑色素瘤伴邻近临床原发性获得性黑变病的患者。
主要发现
- 12周治疗时,结膜上皮内瘤变伴中度异型增生达完全临床和组织学缓解。
- 12周治疗时,鳞状细胞癌部分组织学缓解(从鳞状细胞癌降级为结膜上皮内瘤变伴中度异型增生)。
- 12周治疗时,鳞状细胞癌切除阳性切缘无组织学复发。
- 12周治疗时,弥漫性原位黑色素瘤部分临床缓解,角膜缘7点钟位置上皮色素轻度持续存在,但初始地图活检区域达完全组织学缓解。
- 15周治疗时,原发性获得性黑变病达完全临床和组织学缓解。
关键数值与推荐
- 复合咪喹莫特5%眼膏涂抹结膜表面,每周5天,至少12周(范围12-15周),联合局部抗生素。
- 主要结局指标为原位黑色素瘤或眼表鳞状上皮肿瘤的组织学缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 仅5例,无法确定确切安全性和疗效。
- 需要更长期随访和更大样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There are limited effective treatment options for diffuse conjunctival melanoma in situ (MIS), diffuse conjunctival intraepithelial neoplasia, and squamous cell carcinoma. There is a need for a more effective treatment with less ocular adverse effects than mitomycin C for MIS and 5-fluorouracil for ocular surface squamous neoplasia (OSSN). OBJECTIVE: To evaluate the outcomes of compounded imiquimod 5% in ophthalmic petrolatum-based ointment for diffuse conjunctival MIS or OSSN. DESIGN, SETTING, AND PARTICIPANTS: This was an interventional case series study at a tertiary referral center conducted from June 2024 to March 2025. Patients with a histological diagnosis of either conjunctival intraepithelial neoplasia (CIN), conjunctival squamous cell carcinoma, conjunctival MIS, or conjunctival melanoma with adjacent clinical primary acquired melanosis (PAM) were included in the study. EXPOSURES: Compounded imiquimod 5% ointment applied to the conjunctival surface 5 days per week for 12 weeks at a minimum (range, 12-15 weeks) along with a topical antibiotic. MAIN OUTCOMES AND MEASURES: Histological resolution of MIS or OSSN. RESULTS: This case series included 5 patients (mean [SD] age, 77.4 [6] years; 4 female [80%]). At 12 weeks of treatment, there was complete clinical and histological response of CIN with moderate dysplasia, partial histological response (downgrade from squamous cell carcinoma to CIN with moderate dysplasia), and no histological recurrence of positive margins of squamous cell carcinoma excision. At 12 weeks of treatment, there was partial clinical response of diffuse MIS with mild persistence of epithelial pigmentation at the corneal limbus at the 7-o'clock position; however, there was complete histological response in the areas of initial map biopsy. At 15 weeks of treatment, there was complete clinical and histological response of PAM. Of the 5 patients, all experienced ophthalmic adverse events only affecting the ocular surface and eyelids. All ocular surface adverse events resolved within 1 to 2 weeks of drug holiday or completing treatment. CONCLUSIONS AND RELEVANCE: Study results suggest that, although definitive safety and efficacy cannot be determined across only 5 cases, compounded imiquimod 5% ointment may be a safe and effective approach to manage diffuse conjunctival MIS or OSSN. Longer-term follow-up with larger number of cases is warranted.
引用
- Bowen RC, Bryar PJ, Gerami P, et al. Imiquimod Treatment for Conjunctival Melanoma In Situ or Ocular Surface Squamous Neoplasia. JAMA Ophthalmol. 2026. PMID: 41296343. doi:10.1001/jamaophthalmol.2025.4669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。